CEO and founder Wayne Paterson discussed the company’s DurAVR transcatheter aortic valve replacement (TAVR) program, recent ...

Six-year follow-up from a trial comparing surgery with TAVR in low-risk patients showed no difference in major events, but ...

Chief Executive Officer Wayne Paterson outlined the company’s DurAVR transcatheter aortic valve replacement (TAVR) program ...

Please provide your email address to receive an email when new articles are posted on . A strategy of local anesthesia without sedation was safe vs. conscious sedation for patients undergoing TAVR.

Edwards Lifesciences (NYSE: EW) and Boston Scientific (NYSE: BSX) both reported strong quarters, but the results reveal fundamentally different strategies in the heart device market. Edwards doubled ...

Please provide your email address to receive an email when new articles are posted on . Transcatheter aortic valve replacement for younger adults with severe aortic stenosis rose nearly ninefold from ...

For the rising number of patients needing aortic reintervention, transcatheter aortic valve replacement (TAVR) explantation carried the highest mortality risk, two registry analyses affirmed. In ...

RANCHO MIRAGE, Calif., Jan. 4, 2024 /PRNewswire/ -- Eisenhower Health is the first hospital in the United States to become an Edwards Benchmark program Case Observation Site for the treatment of ...

From 2015 to 2020, the number of patients opting for valve-in-valve transcatheter aortic valve replacement (ViV-TAVR) over redo surgical aortic valve replacement (SAVR) rose significantly, from 35.3% ...

Transcatheter aortic valve replacement (TAVR) has revolutionized the treatment of aortic valve stenosis. With proven safety and efficacy, TAVR has become a standard therapeutic alternative to surgical ...

Add Yahoo as a preferred source to see more of our stories on Google. Edwards Lifesciences' Sapien 3 Ultra system. The artificial heart valve is pushed through the blood vessels via a catheter and ...